For once, let us talk about business!
For the second year in a row, our Managing Director Cesar Carnicer was interviewed by Joseph Harvey (Animal Pharm), business analyst for IHS Markit.
For sure, in these times of pandemic, we all need to read, hear and talk about things that are going well and bring a little positivity to our daily lives. Although we are rather discreet on the subject, for once we are going to talk about Syva from a more ‘business’ angle.
As this economic analyst’s evocatively titled article points out: ‘Syva’s investment in burgeoning vaccine business undeterred by pandemic’, Syva has remained solid despite the sanitary threat and has been well advised to continue developing its vaccine production activities, which now account for a third of its turnover and which reached a decisive turning point in 2019 with the launch of its multi-strain vaccine against blue tongue disease.
If we had to give some achievements of Syva’s activity in 2020, it is
- A growing turnover;
- A storage capacity that has almost doubled;
- A storage capacity linked to the cold chain dedicated to vaccines that has tripled;
- The establishment of a new subsidiary in Turkey which opens up new horizons;
- The perspective of launching new vaccines that will strengthen its own product portfolio with high focus on quality.
These are all reasons and opportunities to renew its commitment to its customers by keeping its focus on its mission to offer ‘meaningful solutions for animal health’.
More details in the interview with César Carnicer, CEO of Syva, by Joseph Harvey (Animal Pharm) for IHS Markit: Syvas_investment_in_burgeoning_vaccine_business_undeterred_by_pandemic-2
For more information on IHS Markit: https://ihsmarkit.com/company/index.html
For more information on Syva: www.syva.es/en
You may also be interested in
2 March, 2023
SYVA announces its partnership with the biotech SMIVET for the development of SDA [SDA]
León - Technology Park – Spain, March 2, 2023 - SYVA and SMIVET signed a collaboration agreement that allow both companies to develop therapeutic solutions based on Single Domain Antibodies (SDA). With this agreement, Syva expresses its willingness to invest in new biotechnologies with the objective to continue to grow and improve its attractiveness by researching, developing, and producing...
15 February, 2023
The earthquake in Turkey affected Syva’s collaborators
From Syva we are wholeheartedly with our colleagues and The Turkish population. We want to express our support in this difficult time. We continue daily to analyse the situation and we evaluate with our contact in Turkey, how we can best support them.
23 December, 2022
Merry Christmas and a Happy New Year 2023!
Time flies and here we are already on the eve of Christmas and New Year’s celebrations for most people around the world. It’s time for us to take a little rest with our families and to wish you wonderful festivities with your family, friends, and why not at home watching a good movie. Each one according to its...